Moderna to reduce COVID-19 vaccine production at Lonza’s Swiss facility

Moderna has revealed its intention to reduce the production of the mRNA drug substance used in its COVID-19 vaccine at Lonza’s Swiss facility during this quarter.

View Full Story

Share:

The Latest